Articles

Merck's Cornerstone Cancer Drug at ASCO: Key Insights

At ASCO, Merck showcased its cornerstone cancer drug, highlighting its potential impact on treatment paradigms and market positioning. This article delves into key insights and implications for pharmaceutical stakeholders.

STAT+: Insights on Pancreatic Cancer Ahead of ASCO 2026

As ASCO 2026 approaches, pancreatic cancer remains a focal point for pharmaceutical advancements. This article explores key developments and their implications for the industry.

Hepatitis B Drug Developments and Lilly's Obesity Drug Returns

This article discusses the latest advancements in hepatitis B drug development and the implications of CVS reinstating Lilly's obesity drug on formularies.

Trump's Pharma Deals Under Scrutiny: Insights and Implications

This article analyzes the recent scrutiny of Trump's pharmaceutical deals, focusing on their implications for business development teams and investors. Key insights and competitive impacts are discussed.

Latest Developments on Ebola, Hepatitis B, and Long Covid

This article covers the most recent developments in Ebola, hepatitis B, and long Covid, highlighting their implications for the pharmaceutical industry.

Ebola at the World Cup: What We Should Really Worry About

This article discusses the potential public health implications of Ebola at the World Cup, focusing on the more pressing health threats that may arise during large events.

Pharma Leaders Advocate for Japan's R&D Investment

Pharma leaders recently met with Japan's Prime Minister Takaichi to discuss strategies for maintaining the country's R&D leadership. This article outlines key takeaways and implications for the pharmaceutical industry.

Oura's Entry into Cuffless Blood Pressure Monitoring

Oura has entered the cuffless blood pressure monitoring space with its new rings. This article explores the implications for the pharmaceutical sector.

ASCO 2026 Preview for Pharma Leaders

This article previews the upcoming ASCO meeting, highlighting critical insights and implications for pharmaceutical professionals. Stay informed on the latest developments in cancer research.

Blood Pressure Tech Market Surge Post-FDA Oversight Changes

The FDA's recent relaxation of oversight on blood pressure wearables has led to a surge in market entries. This article explores the implications for pharmaceutical teams.

FDA Alert: Infectious Diseases Drug News Roundup 2026

This article provides a comprehensive roundup of the latest FDA alerts regarding infectious diseases drug trials in 2026, highlighting key implications for stakeholders.

AstraZeneca's Imfinzi Secures Second Bladder Cancer Approval

AstraZeneca's Imfinzi has gained a second approval for bladder cancer treatment, marking a significant milestone in its development. This article explores the implications for the pharmaceutical landscape.

Research Progress and Development Strategies of Antibody-Oligonucleotide Conjugates

This article provides an in-depth analysis of the recent progress in antibody-oligonucleotide conjugates, focusing on clinical trials and their strategic implications for the pharmaceutical industry.

Ebola Outbreak Response: U.S. Fortification Strategies

As the Ebola outbreak escalates in Central Africa, the U.S. implements stringent measures. This article examines the implications for the pharmaceutical sector.

FDA PreCheck Pilot Program Launches: A New Era for Clinical Trials

The FDA's PreCheck Pilot Program aims to streamline clinical trial approvals, offering significant implications for pharmaceutical companies and investors. This article analyzes the program's launch and its potential impact on the industry.

GSK and Ionis Present Promising Hepatitis B Drug Data

GSK and Ionis have unveiled significant data on their hepatitis B drug, presenting a potential functional cure. This development could reshape treatment strategies in the pharmaceutical industry.

Trump Drug Pricing Deals Face New Launches

As new pharmaceutical products are set to launch, Trump's drug-pricing deals face critical scrutiny. This article delves into the implications for business development teams and investors.

Hepatitis B Functional Cure Data From GSK

Recent findings indicate that an experimental treatment for hepatitis B has achieved a functional cure in nearly one in five patients, signaling potential shifts in the market.

Stem-Cell Heart Patch Shows Early Benefit

A groundbreaking heart patch developed from stem cells shows promise in revitalizing weakened hearts. This article explores its implications for the pharmaceutical industry.

Verge Rebrands After ALS AI Drug Failure

Verge's recent trial failure prompts a strategic rebranding of its AI drug discovery initiatives. This article explores the implications for the pharmaceutical industry.